Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

2(50.0%)

N/A

2(50.0%)

4Total

Phase 4(2)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03495908Not ApplicableCompleted

Regular Insulin vs Rapid Insulin Delivered by V-Go

Role: collaborator

NCT01326598Completed

Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting

Role: lead

NCT02361489Phase 4Unknown

Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices

Role: lead

NCT00486109Not ApplicableCompleted

A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port

Role: collaborator

NCT00453934Phase 4Terminated

Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device

Role: lead

All 5 trials loaded